Table 4.
Other antibody-functionalized lipid nanoparticles for anticancer drug delivery.
| Nanocarrier | Drug | Ligands | Coupling Method | Cancer Cell (In Vitro) | Cancer (In Vivo) | Ref. |
|---|---|---|---|---|---|---|
| Lipid–polymer hybrid NP | Paclitaxel | CEA half-Ab | Maleimide | BxPC-3 XPA-3 (pancreatic) |
- | [94] |
| Lipid–polymer hybrid NP | Adriamycin | EGFR Fab’ | Maleimide | SMMC-7721 HepG2 Huh7 |
HCC | [95] |
| Lipid–polymer hybrid NP | Salinomycin | CD44 Fab’ | Maleimide | DU145 22RV1 |
Prostate | [96] |
| Lipid–polymer hybrid NP | Cisplatin 5-Fluorouracil |
Trastuzumab | Carbodiimide | BE-3 | Esophageal | [97] |
| Lipid–polymer hybrid NP | Ara-C | CD33 mAb or Fab’ | Maleimide | HL-60 | AML | [98] |
| Lipid nanovesicles | - | EGFR mAb | Maleimide | DU145 (prostate) A431 (epidermoid carcinoma) |
- | [99] |
| Niosome | Daunorubicin | CD123 | Maleimide | NB4 THP-1 |
AML | [101] |
| Cubosome | Paclitaxel | EGFR 528 Fab’ | Maleimide | HEY | Ovarian | [102] |
AML, acute myeloid leukemia; Ara-C, 1-β-D-arabinofuranosylcytosine; CD, cluster of differentiation; CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; HCC, hepatocellular carcinoma; NP, nanoparticle.